Background And Purpose: We recently identified mutations in the a3 (VI) collagen gene COL6A3 that cause autosomal-recessive isolated dystonia (DYT27). This article gives a detailed description of the clinical phenotype associated with this new type of dystonia.

Methods: A total of 5 recessive COL6A3 mutation carriers underwent clinical examinations, and case histories were recorded on videotape.

Results: Biallelic COL6A3 mutations cause isolated dystonia with interindividual heterogeneity of distribution and severity. Dystonia was generalized in 3 patients, pronounced in the cranio-cervical region, upper limbs, and trunk; segmental in 1 patient, with the neck and upper limbs affected; and focal with cervical involvement in another patient. Symptoms began in childhood, adolescence, or early adulthood, initially affecting the neck as cervical dystonia or the hand as writer's cramp.

Conclusion: COL6A3-associated dystonia represents a newly identified autosomal-recessive entity characterized clinically by an early symptom onset with variable distribution. © 2015 Movement Disorder Society.

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.26501DOI Listing

Publication Analysis

Top Keywords

isolated dystonia
12
clinical phenotype
8
recessive col6a3
8
col6a3 mutations
8
upper limbs
8
dystonia
6
phenotype early-onset
4
early-onset isolated
4
dystonia caused
4
caused recessive
4

Similar Publications

Introduction: Functional thalamic surgery is known for alleviating isolated focal hand dystonia; however, the optimal target site in the thalamus is not determined. This study aimed to identify effective sites for thalamic deep brain stimulation (DBS) in treating this condition.

Methods: Four patients presenting with focal hand dystonia underwent thalamic DBS.

View Article and Find Full Text PDF
Article Synopsis
  • The globus pallidus internus (GPi) is the primary target for deep brain stimulation (DBS) in dystonia treatment, but some patients show low response rates.
  • A survey of DBS clinicians revealed that over 85% frequently use alternative targets, like the subthalamic nucleus, especially for patients who do not respond well to GPi-DBS.
  • There is a need for more research on the effectiveness of these alternative targets and better criteria for identifying nonresponding dystonia patients.
View Article and Find Full Text PDF

Background: Bilateral deep brain stimulation (DBS) of subthalamic nucleus (STN) has demonstrated efficacy for ameliorating medication-refractory isolated dystonia. Nonetheless, the paucity of evidence regarding its long-term impact on quality-of-life (QoL) necessitates further investigation.

Objectives: This study aimed to elucidate the longitudinal effects of chronic STN stimulation on QoL in patients suffering from isolated dystonia.

View Article and Find Full Text PDF

Engaging dystonia networks with subthalamic stimulation.

Proc Natl Acad Sci U S A

January 2025

Center for Brain Circuit Therapeutics, Department of Neurology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA 02115.

Deep brain stimulation is an efficacious treatment for dystonia. While the internal pallidum serves as the primary target, recently, stimulation of the subthalamic nucleus (STN) has been investigated. However, optimal targeting within this structure and its surroundings have not been studied in depth.

View Article and Find Full Text PDF

Background: Dystonia may respond to VMAT2 inhibition.

Objectives: Providing pilot data on the safety, tolerability, and efficacy of deutetrabenazine in non dopa-responsive dystonia.

Methods: Deutetrabenazine was titrated by adults with isolated dystonia.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!